Join MySLAS Social

Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development

Read this Article

Bernard Fermini, Ph.D.
Chief Scientific Officer
Vice President of Safety and Toxicology Assessment
Coyne Scientific
Atlanta, GA (USA)

Bernard Fermini earned a Ph.D. in biophysics from the University of Sherbrooke (Canada) and completed postdoctoral training at Texas Tech University Health Sciences Center in Lubbock, TX. He joined the Montreal Heart Institute (Québec, Canada) where he led a team in the discovery of a novel atrial selective K+ ion channel in humans.

Fermini then moved to Merck in Pennsylvania and worked on atrial antiarrhythmic agents before joining Pfizer Research in Groton, CT, where he held positions of increasing responsibilities including associate director of Global Safety Pharmacology, and head of the Ion Channel Discipline. Fermini is currently vice president of safety and toxicology assessment and chief scientific officer at Coyne Scientific, focusing on the role of genetic diversity in defining, in vitro, drug responses within a target population.

Websites
Coyne Scientific
LinkedIn

Other SLAS Publications
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm


SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

August 20, 2018